Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering

Rhea-AI Summary

Anteris Technologies Global Corp. (AVR) has completed its U.S. initial public offering, raising $88.8 million through the sale of 14.8 million shares at $6.00 per share. The company began trading on NASDAQ on December 13, 2024, under ticker 'AVR'. An additional $13.3 million could be raised if underwriters exercise their Green Shoe option for 2.22 million shares.

The company plans to list its CHESS Depositary Interests on ASX on December 17, 2024. Proceeds will primarily fund the development of DurAVR® transcatheter heart valve and a global pivotal study for treating severe aortic stenosis, with remaining funds allocated to working capital and debt repayment.

Positive

• Successfully raised $88.8 million through IPO
• Potential additional $13.3 million from Green Shoe option
• Dual listing strategy on NASDAQ and ASX enhances market access
• Clear allocation of funds towards product development and clinical trials

Negative

• Existing debt requiring repayment from IPO proceeds
• Significant dilution of ownership through 14.8 million new shares
• Additional potential dilution from 2.22 million Green Shoe shares

Insights

Financial Analyst

This successful $88.8 million IPO marks a significant milestone for Anteris Technologies, providing substantial capital for their DurAVR® transcatheter heart valve development. The dual listing strategy on NASDAQ and ASX enhances market accessibility and liquidity. The pricing at $6.00 per share with a potential additional $13.3 million through the Green Shoe option demonstrates strong institutional interest. The involvement of major underwriters like TD Cowen, Barclays and Cantor adds credibility to the offering. The proceeds will primarily fund the pivotal global study for DurAVR® THV, which is important for market approval and commercialization in the lucrative cardiovascular device market.

Medical Research Analyst

The successful IPO funding significantly advances Anteris's position in the transcatheter aortic valve replacement (TAVR) market. The DurAVR® THV represents an important innovation in treating severe aortic stenosis, a condition affecting millions globally. The substantial capital raise will accelerate the randomized global pivotal study, important for regulatory approval. This positions Anteris to compete in the rapidly growing TAVR market, currently dominated by established players. The focus on severe aortic stenosis treatment aligns with increasing demand for minimally invasive cardiac procedures in aging populations.

BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)-- Anteris Technologies Global Corp. (“ATGC” or “Anteris”) is pleased to announce the closing of its initial public offering of 14,800,000 shares of its common stock (the “Common Stock”) in the U.S. at a price of $6.00 per share (the “Offering”). An additional 2,220,000 shares of Common Stock are issuable pursuant to the underwriters’ option to purchase additional shares of Common Stock from ATGC (the “Green Shoe”), if exercised in full. ATGC’s Common Stock is listed on the Nasdaq Global Market (“NASDAQ”) from December 13, 2024, trading under the ticker symbol “AVR.”

The aggregate gross proceeds to ATGC from the Offering were approximately $88.8 million ($A 138.4 million) prior to underwriting discounts, commissions and other estimated offering expenses. If the underwriters exercise the Green Shoe in full, ATGC will receive an additional approximately $13.3 million prior to underwriting discounts and commissions.

TD Cowen, Barclays and Cantor acted as joint book-running managers for the Offering, with Lake Street Capital Markets as lead manager.

On December 17, 2024, ATGC will list its CHESS Depositary Interests (“CDIs”) (representing underlying shares of Common Stock on a 1 CDI-for-1 share of Common Stock basis) on the ASX under the ticker symbol “AVR.”

Anteris currently intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents, primarily for the ongoing development of its DurAVR^® transcatheter heart valve (“DurAVR^® THV”) and the preparation and enrolment of a randomized global pivotal study of DurAVR^® THV for treating severe aortic stenosis, with the remaining for working capital and other general corporate purposes determined from time to time, including the repayment of amounts owed under its convertible note facility.

A registration statement relating to the Common Stock issued in the Offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on December 12, 2024. A final prospectus relating to the Offering was filed with the SEC on December 13, 2024. This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation or sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The Offering was and is being made only by means of a prospectus. Copies of the final prospectus relating to the Offering may be obtained from: TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846 or by e-mail at TD.ECM_Prospectus@tdsecurities.com; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue Edgewood, NY 11717, by telephone at (888) 603-5847 or by e-mail at Barclaysprospectus@broadridge.com; or Cantor Fitzgerald & Co., 110 East 59th Street, 6th Floor, New York, NY 10022, by telephone at (212) 915-1800 or by e-mail at prospectus@cantor.com.

About Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR)

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris’ lead product, the DurAVR^® Transcatheter Heart Valve (“THV”), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR^® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.

DurAVR^® THV is made using a single piece of molded ADAPT^® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT^® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The DurAVR^® THV System is comprised of the DurAVR^® valve, the ADAPT^® tissue, and the balloon-expandable ComASUR^® Delivery System.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “intend,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements include the anticipated use of the net proceeds of the Offering, the listing of the CDIs on the ASX and Anteris’ pivotal study. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in ATGC’s registration statement relating to the Offering. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, neither ATGC or Anteris assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

Authorization and Additional information

This press release was authorized by the Board of Directors of Anteris Technologies Global Corp.

Website		www.anteristech.com
X		@AnterisTech
Facebook		www.facebook.com/anteristech
LinkedIn		https://www.linkedin.com/company/anteristech

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241216426257/en/

Investor Relations

investors@anteristech.com

Anteris Technologies Global Corp.

+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

Malini Chatterjee, Ph.D.

Managing Director

Blueprint Life Science Group

+1 917 330 4269

Source: Anteris Technologies Global Corp.

FAQ

How much did Anteris Technologies (AVR) raise in its IPO?

Anteris Technologies raised $88.8 million ($A 138.4 million) through its IPO by selling 14.8 million shares at $6.00 per share.

When did AVR start trading on NASDAQ?

AVR began trading on the NASDAQ Global Market on December 13, 2024.

What is the size of AVR's Green Shoe option?

The Green Shoe option allows underwriters to purchase an additional 2.22 million shares, potentially raising an extra $13.3 million.

How will AVR use its IPO proceeds?

The proceeds will primarily fund DurAVR® transcatheter heart valve development, a global pivotal study for severe aortic stenosis treatment, working capital, and debt repayment.

When will AVR list its CDIs on the ASX?

AVR will list its CHESS Depositary Interests (CDIs) on the ASX on December 17, 2024, under the ticker symbol 'AVR'.